1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014

Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014" provides data on the Relapsed Acute Myeloid Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Relapsed Acute Myeloid Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Relapsed Acute Myeloid Leukemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Relapsed Acute Myeloid Leukemia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Relapsed Acute Myeloid Leukemia 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Relapsed Acute Myeloid Leukemia 33
Aug 28, 2013: Astex Pharmaceuticals Announces Topline Results of SGI-110 AML Phase 2 Study 33
Jun 25, 2013: FDA Issues Partial Clinical Hold On Cell Therapeutics's Tosedostat For Treatment Of Blood Cancer 33
Jun 13, 2013: Sunesis Pharma Announces Data And Safety Monitoring Board Recommends Continuation Of VALOR Trial With No Change To Study Conduct 33
Apr 01, 2013: Clavis Pharma Reports Negative Outcome Of Phase III CLAVELA Trial With Elacytarabine In Patients With Acute Myeloid Leukemia 34
Nov 28, 2012: Coronado Biosciences Initiates Phase I/II Trial Of CNDO-109 Activated Allogeneic Natural Killer Cells In Acute Myeloid Leukemia 34
Clinical Trial Profiles 36
Clinical Trial Overview of Top Companies 36
Novartis AG 36
Clinical Trial Overview of Novartis AG 36
Pfizer Inc. 38
Clinical Trial Overview of Pfizer Inc. 38
Sanofi 39
Clinical Trial Overview of Sanofi 39
C. H. Boehringer Sohn AG and Co. KG 40
Clinical Trial Overview of C. H. Boehringer Sohn AG and Co. KG 40
Ambit Biosciences Corporation 41
Clinical Trial Overview of Ambit Biosciences Corporation 41
F. Hoffmann-La Roche Ltd. 42
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 42
Chroma Therapeutics Ltd. 43
Clinical Trial Overview of Chroma Therapeutics Ltd. 43
Celator Pharmaceuticals, Inc. 44
Clinical Trial Overview of Celator Pharmaceuticals, Inc. 44
AROG Pharmaceuticals LLC 45
Clinical Trial Overview of AROG Pharmaceuticals LLC 45
Amgen Inc. 46
Clinical Trial Overview of Amgen Inc. 46
Clinical Trial Overview of Top Institutes / Government 47
National Cancer Institute 47
Clinical Trial Overview of National Cancer Institute 47
Fred Hutchinson Cancer Research Center 50
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 50
The University of Texas M. D. Anderson Cancer Center 52
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 52
Children's Oncology Group 53
Clinical Trial Overview of Children's Oncology Group 53
Washington University School of Medicine 54
Clinical Trial Overview of Washington University School of Medicine 54
Stanford University 55
Clinical Trial Overview of Stanford University 55
Roswell Park Cancer Institute 56
Clinical Trial Overview of Roswell Park Cancer Institute 56
University of California, San Francisco 57
Clinical Trial Overview of University of California, San Francisco 57
Case Comprehensive Cancer Center 58
Clinical Trial Overview of Case Comprehensive Cancer Center 58
Five Key Clinical Profiles 59
Appendix 116
Abbreviations 116
Definitions 116
Research Methodology 117
Secondary Research 117
About GlobalData 118
Contact Us 118
Disclaimer 118
Source 119

List of Tables
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region, 2014* 7
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Relapsed Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 36
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 38
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 39
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG and Co. KG, 2014* 40
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Ambit Biosciences Corporation, 2014* 41
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 42
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Chroma Therapeutics Ltd., 2014* 43
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Celator Pharmaceuticals, Inc., 2014* 44
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by AROG Pharmaceuticals LLC, 2014* 45
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 46
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 47
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014* 50
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 52
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014* 53
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 54
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 55
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2014* 56
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 57
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 58

List of Figures
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Relapsed Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 117

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market  Forecast-2023

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic lymphocytic leukemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.